关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-095 号 一心堂药业集团股份有限公司 第 1 页 共 2 页 一心为民 全心服务 一心堂药业集团股份有限公司（以下简称"公司"）于2025年10月17日收到保荐机构东兴 证券股份有限公司（以下简称"东兴证券"）发来的《关于更换持续督导保荐代表人的函》。 东兴证券为公司2018年度公开发行可转换公司债券的保荐机构，截至目前，持续督导期已届满， 但公司募集资金尚未使用完毕，根据相关规定，东兴证券对此次未尽事项继续履行持续督导义 务。 东兴证券原指派的保荐代表人周磊先生因工作变动无法继续履行督导职责，为保证公司持 续督导工作的正常进行，东兴证券决定自2025年10月17日起委派马证洪先生（简历附后）接替 周磊先生担任公司持续督导期保荐代表人，继续履行督导职责。 本次保荐代表人变更后，公司持续督导期保荐代表人为朱海洲先生和马证洪先生。根据《证 券发行上市保荐业务管理办法》《深圳证券交易所上市公司保荐工作指 ...

Core Viewpoint - Yixintang Pharmaceutical Group is facing significant compliance and management challenges due to repeated violations of medical insurance regulations, which have led to administrative penalties and a sharp decline in financial performance [1][2][4]. Compliance Risks - The recent administrative penalty against Yixintang's Deqin store involved the return of 1,246.65 yuan in improper medical insurance funds and a fine of double that amount. Similar violations have been reported across multiple locations in 2025, indicating a pattern of non-compliance [2][3]. - In May 2024, the National Medical Insurance Administration had previously warned Yixintang about issues such as drug substitution and excessive prescriptions, leading to a self-inspection that returned over 10.7 million yuan in improper funds. However, ongoing violations suggest that corrective measures have not been effective [2][3]. Management Challenges - As of June 30, 2025, Yixintang operated 11,372 stores across several provinces, but the rapid expansion has not been matched by improvements in management capabilities. The National Medical Insurance Administration highlighted that practices like excessive prescriptions reflect a focus on sales performance at the expense of compliance [3][4]. Financial Performance - Yixintang's financial health is deteriorating, with net profit plummeting from 5.49 billion yuan in 2023 to 1.14 billion yuan in 2024, a year-on-year decline of 79.23%. In the first half of 2025, revenue fell by 4.20%, and net profit decreased by 11.44%, alongside a reduction of 126 stores since the beginning of the year [4][5]. Regulatory Environment - Starting April 1, 2025, new regulations mandating electronic prescriptions have complicated operational processes, negatively impacting efficiency and customer experience. This has contributed to a decline in prescription drug sales [6][7]. - Additional pressures include a narrowing scope of medical insurance payments, declining profit margins, and discrepancies in online and offline regulatory oversight, further straining the company's operations [7]. Challenges Ahead - Yixintang faces dual challenges of ongoing compliance issues and the need to adapt to industry policy changes while grappling with stagnant growth. The company's ability to strengthen internal controls and standardize operations will be crucial for maintaining its medical insurance qualification, brand reputation, and regulatory standing in the capital market [8].

一心为民 全心服务 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理到期收回的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 根据 2024 年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进 行现金管理，现部分产品到期收回，具体如下： 股票代码：002727 股票简称：一心堂 公告编号：2025-094 号 | 签约银行 | 产品名称 | 金额 （万元） | 收益 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-093 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生部分股票质押融资到期还款解除质押 及进行股票质押式回购交易延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）接到公司股东阮鸿献先生通知，获悉 阮鸿献先生与国泰海通证券股份有限公司（以下简称"国泰海通"）达成协议，将 2024 年 10 月 15 日向国泰海通申请办理的股票质押融资业务进行到期还款并解除股票质押；将 2024 年 11 月 6 日向国泰海通申请办理的股票质押融资业务办理股票质押延期购回，具体事项如下： 一、到期还款解除股票质押情况 根据相关资料，阮鸿献先生与国泰海通协商将 2024 年 10 月 15 日向国泰海通申请办理的股 票质押融资业务进行到期还款并解除质押，质押股份数 440 万股，本次全部解除质押。具体如 下： | 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所持 | 占公司 | | | 质权人/申 | 备注 | | -- ...

Core Viewpoint - YXHT Pharmaceutical Group Co., Ltd. has been penalized for violations related to excessive prescription, failure to verify insurance credentials, and selling prescription drugs without a prescription, leading to a total fine of 3,740.95 yuan [1][2]. Group 1: Regulatory Actions - The Deqin County Medical Security Bureau ordered YXHT to rectify the misuse of medical insurance funds and return 1,246.65 yuan [1]. - A fine of 2,493.3 yuan was imposed for the violations, which is double the amount of the misused funds [1]. - The National Medical Security Bureau had previously reported similar issues with YXHT's chain stores, including drug swapping and non-compliance with prescription drug sales [2]. Group 2: Compliance Requirements - YXHT is required to enhance internal control systems, develop marketing regulations, and improve store management practices [2]. - The company must conduct regular compliance checks and strengthen employee education on legal compliance [2]. - YXHT is also expected to play a role in educating insurance beneficiaries about the lawful use of medical insurance funds [2].

Core Viewpoint - Yunnan Zhaotong's Yixin Hall Pharmaceutical Group was penalized for violations related to excessive prescription, failure to verify insurance credentials, and selling prescription drugs without a prescription, leading to a total fine of 3,740.95 yuan [1] Group 1: Regulatory Actions - The Deqin County Medical Security Bureau ordered Yixin Hall to rectify its misuse of medical insurance funds and return 1,246.65 yuan [1] - A fine of 2 times the amount of the misused funds was imposed, totaling 2,493.30 yuan [1] Group 2: Previous Issues - In 2024, the medical insurance department reported that some of Yixin Hall's designated chain stores were involved in issues such as drug switching, excessive prescriptions, and improper sales of prescription drugs, resulting in losses to the medical insurance fund [1][2] - The National Medical Insurance Bureau's Fund Supervision Division had previously conducted discussions with Yixin Hall's management regarding these violations [2]

Core Viewpoint - YXHT (Yixin Tang) has faced multiple administrative penalties for non-compliance with medical insurance fund usage regulations, indicating significant issues in its operational management and compliance practices [1][3][4]. Regulatory Penalties - On October 12, 2025, YXHT's Deqin He Xiang Zhong Lu store was fined for excessive prescriptions, failure to verify insurance credentials, and selling prescription drugs without a prescription, resulting in a total penalty of 3,740.95 yuan (including a refund of 1,246.65 yuan and a fine of 2,493.30 yuan) [1][2]. - The company has been penalized multiple times in recent years, with a total of 10.7 million yuan related to non-compliance issues identified across various stores [6][12]. Financial Performance - YXHT's financial performance has deteriorated significantly, with net profits dropping from 5.49 billion yuan in 2023 to 1.14 billion yuan in 2024, marking declines of 45.60% and 79.23% year-on-year, respectively [14]. - As of June 30, 2025, YXHT operated 11,372 stores, a net decrease of 126 stores since the beginning of the year, with a revenue of 89.14 billion yuan, down 4.20% year-on-year [15]. Business Transformation - YXHT is undergoing a transformation to adapt to changing market conditions, focusing on a dual-track model that includes 30% professional pharmacies and 70% diversified retail stores [16][21]. - The company plans to renovate 1,000 drugstore locations by the end of 2025, with 500 in Yunnan and 500 in other provinces, aiming to enhance customer demand through an expanded product range [21]. Compliance and Regulatory Environment - The company has been under scrutiny from the National Medical Insurance Bureau, which has highlighted issues such as false prescriptions and excessive drug dispensing, necessitating stricter self-management and compliance measures [13][14]. - New regulations effective April 1, 2025, require electronic prescriptions for all dual-channel pharmacies, complicating operational processes and impacting customer experience [16].

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-092 号 一心堂药业集团股份有限公司 根据2024年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进行 现金管理，现部分产品到期收回，具体如下： | 投资主体 | 签约银行 | 产品名称 | 金额 （万元） | 收益类型 | 合同起始日 | 合同到期日 | 收益（元） | | --- | --- | --- | --- | --- | --- | --- | --- | | 一心堂药 | 上海浦东 | 利多多公司稳 | | | | | | | | 发展银行 | 利 25JG3291 期 | | | | | | | 业集团股 | | | | 保本浮动 | | | | | 份有限公 | 股份有限 | (3 个月早鸟款) | 7,500 | 收益型 | 2025-07-14 | 2025-10-14 | 356,250.00 | | | 公司昆明 | 人民币对公结 | | | | | | | 司 | 分行 | 构性存款 | | | | | | 二、过去 12 个月公司使用暂时闲置募集资金进行现金管理的情况 第 1 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-091 号 一心堂药业集团股份有限公司 | 中信银行 | 共赢智信利率 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 股份有限 | 挂钩人民币结 | 5,000 | 保本浮动收 | 2025-10-13 | 2026-01-11 | 1%-2.1% | | 公司昆明 | 构性存款 | | 益型 | | | | | 分行 | A14739 期 | | | | | | | | 广发银行"物华 | | | | | | | | 添宝"W 款 2025 | | | | | | | 广发银行 | 年第 1199 期定 | | | | | 0.5%或 | | 股份有限 | 制版人民币结 | 5,000 | 保本浮动收 | 2025-10-14 | 2026-01-14 | 1.83%或 | | 公司昆明 | 构性存款(挂钩 | | 益型 | | | | | 万宏支行 | 黄金现货看涨 | | | | | 1.9% | | | 阶梯式)(昆明 | | | | | | | | ...

Market Overview - The pharmaceutical commercial sector increased by 0.17% on October 14, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.19, up 1.35% with a trading volume of 48,200 shares and a transaction value of 127 million [1] - China Pharmaceutical (600056) closed at 11.26, up 1.26% with a trading volume of 278,600 shares and a transaction value of 313 million [1] - Dazhenlin (603233) closed at 16.81, up 1.14% with a trading volume of 75,200 shares [1] - Other notable performers include Jianfa Zhixin (301584) up 1.01% and Renmin Tongtai (600829) also up 1.01% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 129 million from institutional investors, while retail investors saw a net inflow of 209 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Saily Medical (603716) had a net inflow of 27.9 million from institutional investors, but a net outflow of 21.2 million from speculative funds [3] - Jianfa Zhixin (301584) saw a net inflow of 11.02 million from institutional investors, with a net outflow of 9.78 million from speculative funds [3] - Yifeng Pharmacy (603939) had a net inflow of 9.47 million from institutional investors, while retail investors experienced a net outflow of 13.37 million [3]